tirzepatide and psoriatic arthritis Concomitant ixekizumab significantly improved disease activity and promoted weight reduction versus ixekizumab alone in adults with PsA and obesity or overweight in the TOGETHER-PsA phase 3b trial. Read Ixekizumab With Tirzepatide Achieved Greater

This slow escalation protocol reduces nausea and allows you to experience steady, predictable weight loss without overwhelming gastrointestinal changes

Its multi-receptor activity offers a novel strategy in metabolic disease, combining appetite suppression, insulin modulation, and increased energy expenditure

Yes, their model is built around regular in-person check-ins for weigh-ins, injections, and picking up supplies

Primary care physicians should be aware that this drug might cause DR progression, so were suggesting that before they start a patient on semaglutide, they should discuss it with an ophthalmologist. Need for caution